Health Canada Approves Orencia (abatacept) for the Treatment of Moderate-to-Severe Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

Bristol-Myers Squibb Canada today announced that Health Canada has approved ORENCIA(R) (abatacept) for reducing signs and symptoms of moderately to severely active juvenile idiopathic arthritis (JIA)/juvenile rheumatoid arthritis in pediatric patients 6 years of age and older who have had an inadequate response to one or more DMARDs, such as MTX .

The details can be read here.